Treatment Approaches for Altered Facial Expression : A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases
Background: Facial weakness is a key feature of facioscapulohumeral muscular dystrophy (FSHD) and may lead to altered facial expression and subsequent psychosocial impairment. There is no cure and supportive treatments focus on optimizing physical fitness and compensation of functional disabilities.
Objective: We hypothesize that symptomatic treatment options and psychosocial interventions for other neurological diseases with altered facial expression could be applicable to FSHD. Therefore, the aim of this review is to collect symptomatic treatment approaches that target facial muscle function and psychosocial interventions in various neurological diseases with altered facial expression in order to discuss the applicability to FSHD.
Methods: A systematic search was performed. Selected studies had to include FSHD, Bell's palsy, Moebius syndrome, myotonic dystrophy type 1, or Parkinson's disease and treatment options which target altered facial expression. Data was extracted for study and patients' characteristics, outcome assessment tools, treatment, outcome of facial expression and or psychosocial functioning.
Results: Forty studies met the inclusion criteria, of which only three studies included FSHD patients exclusively. Most, twenty-one, studies were performed in patients with Bell's palsy. Studies included twelve different therapy categories and results were assessed with different outcomes measures.
Conclusions: Five therapy categories were considered applicable to FSHD: training of (non-verbal) communication compensation strategies, speech training, physical therapy, conference attendance, and smile restoration surgery. Further research is needed to establish the effect of these therapies in FSHD. We recommend to include outcome measures in these studies that cover at least cosmetic, functional, communication, and quality of life domains.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of neuromuscular diseases - (2024) vom: 21. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rasing, Nathaniël B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(MeSH terms): Muscular dystrophy |
|---|
| Anmerkungen: |
Date Revised 22.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.3233/JND-230213 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM37007372X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM37007372X | ||
| 003 | DE-627 | ||
| 005 | 20240323235930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JND-230213 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1343.xml |
| 035 | |a (DE-627)NLM37007372X | ||
| 035 | |a (NLM)38517799 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rasing, Nathaniël B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment Approaches for Altered Facial Expression |b A Systematic Review in Facioscapulohumeral Muscular Dystrophy and Other Neurological Diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Background: Facial weakness is a key feature of facioscapulohumeral muscular dystrophy (FSHD) and may lead to altered facial expression and subsequent psychosocial impairment. There is no cure and supportive treatments focus on optimizing physical fitness and compensation of functional disabilities | ||
| 520 | |a Objective: We hypothesize that symptomatic treatment options and psychosocial interventions for other neurological diseases with altered facial expression could be applicable to FSHD. Therefore, the aim of this review is to collect symptomatic treatment approaches that target facial muscle function and psychosocial interventions in various neurological diseases with altered facial expression in order to discuss the applicability to FSHD | ||
| 520 | |a Methods: A systematic search was performed. Selected studies had to include FSHD, Bell's palsy, Moebius syndrome, myotonic dystrophy type 1, or Parkinson's disease and treatment options which target altered facial expression. Data was extracted for study and patients' characteristics, outcome assessment tools, treatment, outcome of facial expression and or psychosocial functioning | ||
| 520 | |a Results: Forty studies met the inclusion criteria, of which only three studies included FSHD patients exclusively. Most, twenty-one, studies were performed in patients with Bell's palsy. Studies included twelve different therapy categories and results were assessed with different outcomes measures | ||
| 520 | |a Conclusions: Five therapy categories were considered applicable to FSHD: training of (non-verbal) communication compensation strategies, speech training, physical therapy, conference attendance, and smile restoration surgery. Further research is needed to establish the effect of these therapies in FSHD. We recommend to include outcome measures in these studies that cover at least cosmetic, functional, communication, and quality of life domains | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (MeSH terms): Muscular dystrophy | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a bell palsy | |
| 650 | 4 | |a facial expression | |
| 650 | 4 | |a facioscapulohumeral | |
| 650 | 4 | |a mobius syndrome | |
| 650 | 4 | |a myotonic dystrophy | |
| 650 | 4 | |a psychosocial functioning | |
| 650 | 4 | |a therapeutics | |
| 700 | 1 | |a van de Geest-Buit, Willianne A |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, On Ying A |e verfasserin |4 aut | |
| 700 | 1 | |a Mul, Karlien |e verfasserin |4 aut | |
| 700 | 1 | |a Lanser, Anke |e verfasserin |4 aut | |
| 700 | 1 | |a van Engelen, Baziel G M |e verfasserin |4 aut | |
| 700 | 1 | |a Erasmus, Corrie E |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Agneta H |e verfasserin |4 aut | |
| 700 | 1 | |a Ingels, Koen J A O |e verfasserin |4 aut | |
| 700 | 1 | |a Post, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Siemann, Ietske |e verfasserin |4 aut | |
| 700 | 1 | |a Groothuis, Jan T |e verfasserin |4 aut | |
| 700 | 1 | |a Voermans, Nicol C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuromuscular diseases |d 2014 |g (2024) vom: 21. März |w (DE-627)NLM246466057 |x 2214-3602 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JND-230213 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 | ||